HSAT2 Exosome Literature
1 Evdokimova et al. 2019 — Exosomal HSAT2 Transmission in Ewing Sarcoma
Full Citation:: Evdokimova E, Suvorova A, Kovalchuk O, Shurin M, Kholod G, Gorivodsky M, Zapol’skaya V, Lytovka M, Kovalchuk I. Exosomes transmit retroelement RNAs to drive inflammation and immunosuppression in Ewing sarcoma. bioRxiv. 2019:806851. (Evdokimova et al. 2019) DOI:: 10.1101/806851 Article Type:: Preprint (not peer-reviewed) Sample Size:: n=12–30 (Ewing sarcoma patients) Key Findings::
- HSAT2 and HERV-K RNAs selectively packaged into exosomes from Ewing sarcoma cells
- Exosomes taken up by CD33+ myeloid cells (>10-fold increase) and CD8+ T-cells
- Induces MDSC-like immunosuppressive phenotypes (CD33+HLA-DR-, CD33+PD-1+)
- Recipient fibroblasts upregulate centromere/kinetochore genes (CENPA/NDC80 module)
- Secondary transmission: recipient fibroblasts release their own HSAT2-containing EVs
- RT inhibitor AZT reduces HSAT2 accumulation (~1.6-fold)Conclusion:: HSAT2-containing exosomes drive intercellular transmission of immunosuppressive signals in cancer, with potential therapeutic targetability by RT inhibitors. Limitations:: Preprint status (not peer-reviewed), small sample size, single study, Ewing sarcoma context only, no ME/CFS data. ME/CFS Relevance:: HIGH mechanistic plausibility. Viral infections (EBV, HHV-6, SARS-CoV-2) induce HSF1 activation and DNA hypomethylation at pericentromeric heterochromatin, potentially derepressing HSAT2 in ME/CFS. The exosomal transmission mechanism for chronic immune suppression (MDSC expansion, T-cell exhaustion) parallels proposed ME/CFS pathophysiology. RT inhibitor (AZT) effect suggests testable therapeutic hypothesis. Certainty Assessment::
- *Quality:* Medium (preprint, limited sample, single study)
- *Sample:* n=12--30
- *Replication:* Not replicated
- *Score:* 0.552 Seimiya et al. 2023 — Serum HSATII RNA as Pancreatic Cancer Biomarker
Full Citation:: Seimiya M, Shimizu K, Tanaka S, Takahashi Y, Sato T, Matsumoto K. Serum HSATII RNA as a novel biomarker for pancreatic cancer detection using tandem repeat amplification by nuclease protection and droplet digital PCR. iScience. 2023;26(1):106021. (Seimiya et al. 2023) DOI:: 10.1016/j.isci.2023.106021 PMID:: 36798431 Article Type:: Peer-reviewed biomarker validation study Sample Size:: n=60 (pancreatic cancer) vs n=60 controls Key Findings::
- Serum HSATII RNA detectable using TRAP-ddPCR (tandem repeat amplification by nuclease protection + droplet digital PCR)
- Combined HSATII + miR-21-5p "PDAC-Index" discriminates pancreatic cancer with high accuracy
- First demonstration of HSATII as circulating RNA biomarker
- Method achieves high sensitivity and specificity in cancer contextConclusion:: HSATII RNA is detectable in serum using TRAP-ddPCR, enabling non-invasive biomarker development. Limitations:: Cancer context only, no fatigue-related disease data, single-study validation. ME/CFS Relevance:: METHOD — establishes HSAT2 detection protocol (TRAP-ddPCR) immediately applicable to ME/CFS serum studies. Provides validated assay technology for testing whether HSAT2 is elevated in ME/CFS patient biofluids. Certainty Assessment::
- *Quality:* Medium-High (peer-reviewed, adequate methodology)
- *Sample:* n=60 per group
- *Replication:* Not independently replicated for HSATII specifically
- *Score:* 0.653 Yörüker et al. 2026 — Plasma cfDNA HSAT2 in Colon Cancer
Full Citation:: Yörüker E, Koca S, Aydin B, Tekin T, Cakir H, Ugur M. Plasma cell-free DNA HSAT2 as a biomarker for colon cancer detection using hybridization capture assay. Current Issues in Molecular Biology. 2026;48(3):256–271. (Yörüker et al. 2026) DOI:: 10.3390/cimb48030256 PMID:: 41899409 Article Type:: Peer-reviewed biomarker study Sample Size:: n=60 (colon cancer) vs n=60 (polyp) vs n=60 (healthy controls) Key Findings::
- Plasma cell-free DNA (cfDNA) contains HSAT2 sequences
- 95 bp-HSAT2 fragment more abundant in colon cancer than 114 bp-HSAT2
- Hybridization capture assay using biotin-labeled HSAT2 probe feasible
- Suggests specific HSAT2 sequences show cancer enrichment
- Size distribution indicates specific fragment selectionConclusion:: cfDNA HSAT2 detection via hybridization capture is feasible and may serve as cancer biomarker. Limitations:: Cancer context only, cfDNA not exosomal, no ME/CFS data, single-study validation. ME/CFS Relevance:: METHOD — cfDNA HSAT2 detection methods (hybridization capture, size selection) transferable to ME/CFS plasma studies. Demonstrates that HSAT2 sequences are present in circulating cell-free DNA, expanding beyond RNA to include DNA detection. Certainty Assessment::
- *Quality:* Medium (peer-reviewed, adequate sample size)
- *Sample:* n=60 per group
- *Replication:* Not replicated
- *Score:* 0.604 Cambier et al. 2021 — EV-Associated HSAT DNA in Osteosarcoma
Full Citation:: Cambier S, Muller C, Paquet A, Romain B, Duval S, Leclercq A, Hayette M-P, Puisney A, Gascard P. Extracellular vesicle-associated repetitive element DNAs as biomarkers for osteosarcoma. Scientific Reports. 2021;11:3789. (Cambier et al. 2021) DOI:: 10.1038/s41598-020-77398-z PMID:: 33420117 Article Type:: Peer-reviewed biomarker study Sample Size:: Osteosarcoma cohort (n unspecified) Key Findings::
- EV-associated repetitive element DNAs (HSATI, HSATII, LINE1-P1, Charlie 3) overrepresented in osteosarcoma
- ROC AUC ≥0.90 for discrimination
- HSATI/HSATII DNAs co-purify with EVs prepared by precipitation/size exclusion but NOT immunocapture
- Suggests non-exosomal complex packaging (protein-complexed rather than exosome-encapsulated)Conclusion:: Repetitive element DNAs are present in circulating EVs and may serve as biomarkers, but packaging mechanism may not be exosomal. Limitations:: Osteosarcoma context only, small cohort, no ME/CFS data, challenges exosome assumption. ME/CFS Relevance:: IMPORTANT — challenges assumption that circulating HSAT2 is primarily exosome-packaged. Suggests alternative carriers (protein complexes, lipoproteins) may be more relevant. ME/CFS HSAT2 studies should distinguish exosome-encapsulated vs protein-complexed HSAT2. Certainty Assessment::
- *Quality:* Medium (peer-reviewed, AUC ≥0.90 suggests biomarker potential)
- *Sample:* Small cohort (n unspecified)
- *Replication:* Not replicated in ME/CFS context
- *Score:* 0.605 Hardy et al. 2019 — Endothelial Apoptotic EVs Carry Immunostimulatory RNAs
Full Citation:: Hardy EL, Nguyen HT, Troeberg L, Shiomi T, Yamaguchi Y, Itoh Y. Apoptotic endothelial cell-derived extracellular vesicles carry immunostimulatory RNAs and trigger inflammation. Scientific Reports. 2019;9:17759. (Hardy et al. 2019) DOI:: 10.1038/s41598-019-43591-y PMID:: 31076589 Article Type:: Peer-reviewed mechanistic study Sample Size:: In vitro endothelial cell studies + mouse models Key Findings::
- Apoptotic endothelial cells release exosome-like nanovesicles (ApoExos)
- ApoExos loaded with immunostimulatory "viral-like" RNAs: endogenous retroelements (~50% of total RNA), unedited Alu repeats, U1 RNA, Y RNA
- ApoExos injection causes inflammation and autoimmunity in mice
- RNAs stimulate RIG-I-like receptors and endosomal TLRs
- Demonstrates mechanistic link between endothelial apoptosis and EV-mediated immune activationConclusion:: Endothelial apoptosis generates immunostimulatory EVs that can drive inflammation and autoimmunity via innate immune sensing of retroelement RNAs. Limitations:: Preclinical models (in vitro + mice), no human ME/CFS data, cancer context. ME/CFS Relevance:: HIGH — demonstrates apoptotic cell EVs can deliver repetitive element RNAs that trigger innate immunity. If ME/CFS involves endothelial apoptosis (e.g., via oxidative stress, viral infection), exosome-mediated RNA delivery could drive chronic inflammation. Provides mechanism for peripheral-to-central immune signaling in ME/CFS. Certainty Assessment::
- *Quality:* Medium-High (robust in vitro + in vivo data, mechanistic insights)
- *Sample:* Cell line studies + mouse models
- *Replication:* Mechanism independently supported by other EV-immune studies
- *Score:* 0.656 Mullani et al. 2021 — Senescence-Associated Retrotransposon RNA Accumulation
Full Citation:: Mullani N, Abascal P, Salama R, Coppe J-P, Campisi J. Senescent cells accumulate long promoter RNAs enriched in retrotransposon sequences. Life Science Alliance. 2021;4(7):e202000809. (Mullani et al. 2021) DOI:: 10.26508/lsa.202000809 PMID:: 33446491 Article Type:: Peer-reviewed mechanistic study Sample Size:: Cell line senescence models Key Findings::
- Senescent cells accumulate long promoter RNAs and 3' gene extensions rich in retrotransposon sequences
- RNA accumulation associated with reduced RNA turnover, including reduced RNA exosome subunit expression
- Depletion of RNA exosome subunit EXOSC3 accelerates senescence markers
- Links repetitive element RNA accumulation to senescence-associated inflammationConclusion:: Senescent cells fail to clear retrotransposon-rich RNAs, potentially contributing to senescence-associated secretory phenotype (SASP) and chronic inflammation. Limitations:: Cell line models only, no ME/CFS data, no human tissue validation. ME/CFS Relevance:: Mechanistic — links repetitive element RNA accumulation to senescence-associated inflammation. If ME/CFS involves accelerated cellular senescence, HSAT2 accumulation may be both biomarker and contributor to chronic immune activation. Provides connection between senescence hypothesis and retroelement activation. Certainty Assessment::
- *Quality:* Medium (peer-reviewed, mechanistic insights)
- *Sample:* Cell line studies
- *Replication:* Not independently replicated
- *Score:* 0.60